0001140361-21-032105.txt : 20210922
0001140361-21-032105.hdr.sgml : 20210922
20210922165724
ACCESSION NUMBER: 0001140361-21-032105
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210920
FILED AS OF DATE: 20210922
DATE AS OF CHANGE: 20210922
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sidhu Roger
CENTRAL INDEX KEY: 0001884115
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11460
FILM NUMBER: 211270155
MAIL ADDRESS:
STREET 1: C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.
STREET 2: 140 58TH STREET, BUILDING A, SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc.
CENTRAL INDEX KEY: 0000748592
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 311103425
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 140 58TH STREET, BUILDING A
STREET 2: SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
BUSINESS PHONE: (212) 582-1199
MAIL ADDRESS:
STREET 1: 140 58TH STREET, BUILDING A
STREET 2: SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
FORMER COMPANY:
FORMER CONFORMED NAME: NTN BUZZTIME INC
DATE OF NAME CHANGE: 20051230
FORMER COMPANY:
FORMER CONFORMED NAME: NTN COMMUNICATIONS INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: ALROY INDUSTRIES INC
DATE OF NAME CHANGE: 19850411
4
1
form4.xml
FORM 4
X0306
4
2021-09-20
0000748592
Brooklyn ImmunoTherapeutics, Inc.
BTX
0001884115
Sidhu Roger
C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.
140 58TH STREET, BUILDING A, SUITE 2100
BROOKLYN
NY
11220
true
See Remarks
Stock Option
9.96
2021-09-20
4
A
0
161300
0
A
2031-09-20
Common Stock
161300
161300
D
Restricted Stock Unit
2021-09-20
4
A
0
80650
0
A
2031-09-20
Common Stock
80650
80650
D
The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on September 20, 2022, and 1/36 of the remaining shares covered thereby vesting on the twentieth day of each calendar month from October 2022 through September 20, 2025, subject to continued service through each vesting date.
Each restricted stock unit represents a contingent right to receive one share of common stock.
The RSU Grant vests and becomes exercisable in four equal installments on September 20 of each of 2022, 2023, 2024 and 2025, provided that it shall vest in full immediately prior to a change in control (as defined in Dr. Sidhu's Executive Employment Agreement, effective September 20, 2021), subject to continued service through each vesting date.
Chief Medical Officer
/s/Bella Zaslavsky, Attorney-in-Fact for Roger Sidhu
2021-09-22